REGULATED INFORMATION
Nyxoah Reports First Quarter 2024 Financial and Operating Results
Announced DREAM U.S. pivotal study achieved primary endpoints
On track for FDA approval as early as end of 2024
Mont-Saint-Guibert, Belgium - May 14, 2024 10:05pm CET / 4:05pm ET - Nyxoah SA
(Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical
technology company focused on the development and commercialization of
innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported
financial and operating results for the first quarter of 2024.
Recent Financial and Operating Highlights
* Reported the DREAM U.S. pivotal study achieved co-primary endpoints on an
intent-to-treat (ITT) basis and demonstrated strong AHI reductions in supine
and non-supine sleep positions.
* The DREAM study achieved a median AHI reduction of 70.8%, a 12-month AHI
responder rate, per the Sher criteria, of 63.5% (p=0.002) on an ITT basis
and a 12-month ODI responder rate of 71.3% (pÂ